TREK-1 Mediates The Alleviative Effects of GABAB Receptor Antagonism on Depression-Like Behavior in Chronic Unpredictable Stress Rats

Jinying Li, Huairui Li, Weizhi Yu, Xiuli Zhai, Hong Xu, Ying Xue, Ye Sun, Xiaonan Zhang, Ye Gao, Lin Gui, Deqin Yu, Shengming Yin, Yi‐Yuan Tang, Zhaoyang XiaoResearch 2021 · DOI

Introduction

Depression remains a leading cause of disability worldwide, necessitating the discovery of novel therapeutic targets. Recent research has highlighted the potential of $\text{GABA}_B$ receptor ($\text{GABA}_B$ R) antagonists as antidepressants. Concurrently, the TWIK-related potassium channel-1 (TREK-1) has emerged as a promising target for neuropsychiatric treatment. This study investigates the functional link between these two systems, specifically whether TREK-1 mediates the antidepressant actions of $\text{GABA}_B$ R antagonists in a rat model of chronic stress.

Experimental Design and Methodology

The researchers employed a Chronic Unpredictable Stress (CUS) model using adult male Sprague-Dawley rats. Over a 27-day period, rats were exposed to various stressors—including restraint, fasting, and cold water swimming—to induce a depression-like state.

To explore the $\text{GABA}_B$ R-TREK-1 pathway, the study used a multi-arm pharmacological approach:

  • $\text{GABA}_B$ R Modulation: Rats received either Baclofen (an agonist) or CGP55845 (an antagonist).
  • TREK-1 Modulation: Spadin was used as a specific TREK-1 blocker.
  • Positive Control: Citalopram, a standard SSRI, was used for comparison.

Behavioral changes were assessed using the Open Field Test (OFT) for exploratory activity and the Sucrose Preference Test (SPT) for anhedonia. Molecular changes were quantified via Western blotting of hippocampal tissue to measure $\text{GABA}_B$ R and TREK-1 protein levels.

Behavioral and Molecular Results

The study found that chronic stress significantly induced depression-like behaviors, characterized by reduced exploratory activity in the OFT and a marked decrease in sucrose preference. These behavioral deficits were accompanied by a significant reduction in TREK-1 protein expression in the hippocampus.

Experimental timeline and the effects of GABA B R and TREK-1 modulation on behavior and protein expression in CUS rats.

Treatment with the $\text{GABA}_B$ R antagonist (CGP55845) or the TREK-1 blocker (Spadin) successfully alleviated these depression-like behaviors. Crucially, CGP55845 reversed the stress-induced decline in TREK-1 protein levels. In contrast, the $\text{GABA}_B$ R agonist (Baclofen) exacerbated behavioral deficits and further suppressed TREK-1 expression. These results indicate that $\text{GABA}_B$ R activity negatively regulates TREK-1 expression in the hippocampus.

The Signaling Cascade

The researchers propose a molecular mechanism where $\text{GABA}_B$ R activation inhibits the $G_{i/o}$ protein pathway, leading to reduced levels of cyclic AMP (cAMP) and decreased Protein Kinase A (PKA) activity. Since PKA typically inhibits TREK-1, the use of a $\text{GABA}_B$ R antagonist effectively removes this inhibition, allowing for increased TREK-1 expression and function. Interestingly, long-term administration of the TREK-1 blocker Spadin also increased TREK-1 protein levels, suggesting a compensatory feedback mechanism.

Conclusion

This study demonstrates that the antidepressant effects of $\text{GABA}_B$ R antagonists are at least partially mediated by the upregulation of TREK-1 channels in the hippocampus. These findings provide a clearer molecular roadmap for developing targeted therapies that bypass broad receptor modulation in favor of specific downstream effectors. Future research should expand this investigation to other brain regions, such as the amygdala and prefrontal cortex, and include female subjects to ensure the findings are broadly applicable across sexes.

Summary updated

Abstract

Abstract GABA B receptor (GABA B R) antagonists are known to have antidepressant effects. TWIK-related potassium channel-1 (TREK-1) plays a role in GABA B R signaling. However, the role of TREK-1 in the antidepressant actions of GABA B R antagonist is still unclear. This study aimed to investigate whether TREK-1 mediates the antidepressant actions of GABA B R antagonist. To investigate this hypothesis, chronic unpredictable stress rats were treated with a GABA B R antagonist, GABA B R agonist, or TREK-1 blocker. Depression-like behavior was assessed by open field tests and sucrose preference tests. GABA B R and TREK-1 protein levels were measured by western blotting. The results demonstrated that the GABA B R antagonist alleviated depression-like behavior and reversed the decrease in hippocampal TREK-1 protein expression that characterizes chronic unpredictable stress rats. Conversely, the GABA B R agonist exacerbated depression-like behavior and further decreased hippocampal TREK-1 protein expression. In addition, the TREK-1 blocker alleviated the depression-like behavior of chronic unpredictable stress rats and increased hippocampal TREK-1 protein expression. These results suggest that the alleviative effects of the GABA B receptor antagonist on depression-like behavior in chronic unpredictable stress rats are at least partially mediated through TREK-1. These novel findings will be helpful for the clinical therapy of depression.
BibTeX
@inproceedings{li2021trek,
  author = {Jinying Li and Huairui Li and Weizhi Yu and Xiuli Zhai and Hong Xu and Ying Xue and Ye Sun and Xiaonan Zhang and Ye Gao and Lin Gui and Deqin Yu and Shengming Yin and Yi‐Yuan Tang and Zhaoyang Xiao},
  title = {{TREK-1 Mediates The Alleviative Effects of GABAB Receptor Antagonism on Depression-Like Behavior in Chronic Unpredictable Stress Rats}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-214760/v1},
}
Figure